We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
For the third time in less than a week, AstraZeneca has entered into a deal to boost its cancer drug pipeline, this time via a $727.5 million licensing and collaboration agreement with Inovio Pharmaceuticals to develop DNA-based immunotherapies. Read More
The Department of Justice is looking into Allergan’s pricing of certain generic drugs as part of a larger federal probe into rising generic prices. Read More
Amarin Pharmaceuticals has a constitutional right to promote its cholesterol-lowering drug Vascepa for an off-label use as long as the communication is truthful and not misleading, a New York federal judge ruled Friday — dealing a blow to FDA efforts to prevent off-label drug promotion. Read More
AstraZeneca is planning to test at least one A2A receptor-blocking compound across a range of cancers, including in combination with the company’s existing immunotherapy portfolio, under a new collaboration with Heptares Therapeutics. Read More
The Indian government has canceled talks with the EU’s chief trade negotiator to protest the European Commission’s ban of scores of generic drugs tested by Hyderabad-based GVK Biosciences. Read More
A bipartisan group of 33 House lawmakers is challenging the Centers for Medicare & Medicaid Services’ plan to lump all biosimilars of the same reference product into a single payment code, arguing that each product deserves a unique code. Read More